EMA Authorised: Vyjuvek (Beremagene geperpavec) — Krystal Biotech Netherlands B.V.

View source ↗

Summary

The European Medicines Agency has authorised Vyjuvek (beremagene geperpavec) for dystrophic epidermolysis bullosa in the EU, with orphan medicine designation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dystrophic Epidermolysis Bullosa

Drugs mentioned

• Vyjuvek

Snippet

Status: Authorised. Therapeutic area: Epidermolysis Bullosa Dystrophica. MAH: Krystal Biotech Netherlands B.V.. Decision date: 26/06/2025. Orphan medicine